🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

Showing page 55 of 857 · Phase 3 first, then by program name

  1. Docetaxel

    Sanofi Pasteur

    Non-small Cell Lung Cancer

    phase 3 small molecule completed

    1 trial

  2. Docetaxel

    AstraZeneca

    Prostate Cancer

    phase 3 small molecule completed

    1 trial

  3. Docetaxel Accord 20 mg/1 ml concentrate for solution for infusion, Trodelvy 200 mg powder for concentrate for solution for infusion

    Gilead Sciences Pty Limited

    Non-small cell lung cancer

    phase 3 small molecule active

    1 trial

  4. Docetaxel+lobaplatin

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Lobaplatin and Gemcitabine in Combination, Second-line Treatments on Advanced Osteosarcoma

    phase 3 small molecule active

    1 trial

  5. Docetaxel, cisplatin and fluorouracil

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Nasopharyngeal Carcinoma

    phase 3 small molecule active

    1 trial

  6. Dociparstat

    Jazz Pharmaceuticals Ireland Limited

    Acute Myeloid Leukemia

    phase 3 small molecule terminated

    1 trial

  7. Dociparstat sodium

    Jazz Pharmaceuticals Ireland Limited

    Coronavirus Disease 2019 (COVID-19)

    phase 3 small molecule terminated

    1 trial

  8. Dolutegravir/abacavir/lamivudine FDC

    ViiV Healthcare B.V.

    Infection, Human Immunodeficiency Virus

    phase 3 small molecule completed

    1 trial

  9. Domvanalimab

    Arcus Biosciences

    Advanced Upper Gastrointestinal Tract Adenocarcinoma

    phase 3 small molecule active

    1 trial

  10. Donanemab, Florbetapir F18, Flortaucipir F18, Flortaucipir, FLORBETAPIR, SODIUM CHLORIDE PH. EUR.

    Eli Lilly Co.

    Alzheimer Disease Dementia Brain Diseases Central Nervous System Diseases Nervous System Diseases Tauopathies Neurodegenerative Diseases Neurocognitive Disorders Mental Disorders

    phase 3 small molecule active

    1 trial

  11. Donepezil

    Universal Integrated

    Osteoarthritis

    phase 3 small molecule active

    1 trial

  12. Donidalorsen

    IONIS PHARMACEUTICALS INC

    Hereditary Angioedema

    phase 3 small molecule active

    4 trials

  13. Donidalorsen

    IONIS PHARMACEUTICALS INC

    Hereditary Angioedema (HAE)

    phase 3 small molecule active

    1 trial

  14. Dordaviprone (ONC201)

    Jazz Pharmaceuticals Ireland Limited

    H3 K27M

    phase 3 small molecule active

    1 trial

  15. DoriDuo, Mebocaína Anti-Inflam, 1.2 mg + 3 mg, comprimidos para chupar, Placebo to Test and Comparator

    Medice Arzneimittel Pütter GmbH & Co. KG

    acute pharyngitis

    phase 3 small molecule active

    1 trial

  16. Doripenem

    Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

    Ventilator-Associated Pneumonia

    phase 3 small molecule terminated

    1 trial

  17. Dose

    United Therapeutics Europe Ltd

    Chronic Migraine, Headache

    phase 3 small molecule terminated

    1 trial

  18. Dostarlimab

    GlaxoSmithKline

    Neoplasms, Head and Neck

    phase 3 small molecule active

    1 trial

  19. Double encapsulated oral transplant of fecal microbiota, Enema transplant of fecal microbiota, Placebo double encapsulated oral transplant of fecal microbiota, Placebo coloscopic transplant of Fecal microbiota

    Pari Pharma GmbH

    Primary Sclerosing Cholangitis

    phase 3 small molecule active

    1 trial

  20. Double encapsulated oral transplant of fecal microbiota, Placebo double encapsulated oral transplant of fecal microbiota

    Pari Pharma GmbH

    Severe Irritable Bowel Syndrome (IBS)

    phase 3 small molecule active

    1 trial

  21. Double-blind 200 mg imsidolimab

    Vanda Pharmaceuticals Netherlands B.V.

    Generalized Pustular Psoriasis

    phase 3 small molecule terminated

    1 trial

  22. Double-blind, randomised clinical study comparing efficacy and safety of Mecloderm® Cream (Test) vs. Lotricomb® Cream (Reference) vs. Vehicle in patients with moderate to severely inflamed candidiasis of the skin

    Alphapharm Pty Ltd

    moderate to severely inflamed candidiasis of the skin

    phase 3 other active

    1 trial

  23. Dovato 50 mg/300 mg film-coated tablets, Biktarvy 50 mg/200 mg/25 mg film-coated tablets

    ViiV Healthcare Pty Ltd

    Human immunodeficiency virus (HIV)

    phase 3 small molecule active

    1 trial

  24. Dovato 50 mg/300 mg film-coated tablets, Dovato 50 mg/300 mg film-coated tablets, REKAMBYS 900 mg prolonged-release suspension for injection, Vocabria 400 mg prolonged-release suspension for injection, Vocabria 600 mg prolonged-release suspension for injection

    ViiV Healthcare Pty Ltd

    HIV-1 infection

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources